Lunit and Discovery Life Sciences Collaborate to Expand AI-Powered Tissue Analysis for Biopharma Research
Collaboration expands access to Lunit's AI-powered pathology platform by combining it with Discovery Life Sciences' global biospecimen and specialty laboratory capabilities, enabling standardized tissue insights for biomarker research and drug...
Lunit Expands AI-Powered Breast Cancer Screening Across the Stockholm Region
Following years of clinical validation and proven real-world performance at Saint Göran, Stockholm Region adopts Lunit INSIGHT MMG as an independent second reader at regional scale SEOUL, South Korea, Sept. 28, 2026 /PRNewswire/ -- Lunit...
Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026
Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading...
Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
Lunit's AACR 2026 presentations showed how AI-driven biomarkers can improve the efficiency of clinical workflows, uncover spatial features of the tumor microenvironment not captured by conventional methods, and enable integrated analysis to better...
Lunit Surpasses 330+ Sites and 1M Annual Screenings as Breast Imaging AI Moves into Clinical Practice
Lunit highlights enterprise AI adoption and FDA-cleared advancements at SBI 2026 SEOUL, South Korea, April 16, 2026 /PRNewswire/ -- At the Society of Breast Imaging (SBI) Annual Symposium, Lunit (KRX:328130), a leading provider of AI for cancer...